ArticleFrontiers in public health2026
Awareness gaps of onchocerciasis in endemic Health district of Kéniéba, Séféto, Dioila, Kati and Selingué in 2021: cross - sectional study in Mali.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Background: Onchocerciasis is still endemic and requiring Mass drug administration (MDA). In Mali, despite more than 15 rounds of treatment, community perception and adherence depend critically on awareness of the disease. This study aimed to assess awareness and knowledge gaps in the context of long-term MDA exposure assess in endemic communities receiving ivermectin MDA. Methods: A cross-sectional survey was conducted in the health districts (HD) of Dioila, Kati, Kéniéba, Séféto and Sélingué in Mali after 2020 ivermectin MDA distribution. The survey involved 12,663 individuals from 2,357 households. Data on knowledge, attitudes, and reasons for drug acceptance were collected using the ODK platform and analyzed with SPSS. Results: Among those who swallowed ivermectin, the primary reasons were to avoid contracting the disease 45.2% (2,689/5952) or to stay healthy 44.0% (2,619/5952), with significant differences across districts ( Conclusion: While awareness of onchocerciasis as a disease is high in most districts after 15 + MDA rounds, critical knowledge gaps persist regarding transmission and treatment purpose. Many individuals take ivermectin for general health or due to instruction rather than specific prevention. Targeted health education to explain transmission and the rationale for MDA is needed to sustain adherence and progress toward elimination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.